Purinergic signalling, despite its unreceptive inception, represents one of the most common signalling mechanisms in cells (Burnstock, 2012; Burnstock and Verkhratsky, 2010) .
Extracellular nucleotides activate autocrine and/or paracrine purinergic signalling via the P2 family of purinergic receptors on the cell surface. Two structurally and functionally distinctive subfamilies of P2 receptors have been defined, namely, P2X
and P2Y (Ralevic and Burnstock, 1998) . The P2X receptors function as ligand-gated cationic channels that are assembled as homo/hetero-trimers from the seven P2X receptor subunits (P2X1-P2X7) (Browne et al., 2010; Hattori and Gouaux, 2012; Khakh and North, 2012; North, 2002) . The P2X receptor ion channels are gated exclusively by extracellular ATP and form a transmembrane pathway for efflux of K + and influx of Na + and Ca 2+ , leading to an increase in the intracellular Ca 2+ concentration ([Ca 2+ ]i) and/or membrane depolarization. The P2Y receptors are classical G-protein-coupled receptors.
Mammalian cells express eight P2Y subtypes (P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11-P2Y14) (Burnstock, 2012; Jacobson et al., 2012; Jacobson and Muller, 2016; Jacobson et al., 2015; von Kügelgen and Harden, 2011 (Amcheslavsky et al., 2015; Parekh, 2010) . In contrast, the P2Y12-P2Y14 receptors are coupled to the G ,i-AC-cAMP signalling pathway, resulting in inhibition of the adenylyl cyclase (AC) activity and reduction in the generation of intracellular cyclic adenosine monophosphate (cAMP). Some P2Y receptors are known to link to additional downstream signalling pathways. For example, the P2Y11 receptor can also associate with the G ,s-AC-cAMP signalling pathway to stimulate AC and elevate the intracellular cAMP level (von Kügelgen and Harden, 2011) . Both P2X and P2Y receptors are widely expressed in excitable and non-excitable cells and play important roles in mediating extracellular nucleotide-initiated purinergic signalling in a plethora of physiological and pathological processes, as have been elegantly covered in numerous recent reviews (Burnstock and Ralevic, 2014; Burnstock and Ulrich, 2011; Burnstock and Verkhratsky, 2010; Jacobson et al., 2012; Jacobson and Muller, 2016; Jiang, 2012; North, 2002; Surprenant and North, 2009; von Kügelgen and Harden, 2011) .
Mesenchymal stem cells (MSC) are a group of non-hematopoietic multipotent stem cells, which were firstly isolated from bone marrow and later also from other adult tissues including adipose tissue, umbilical cord, periodontal ligament and dental pulp. MSC are well-documented to differentiate into adipocyte, osteoblast and chondrocyte (Bianco, 2014; Dominici et al., 2006; Pittenger et al., 1999) , the important cell types in adipose, bone and cartilaginous tissues, respectively. Emerging evidence suggests the potential of differentiation into other lineages, such as neuronal (Tu et al., 2014) and Schwann glial cells (Faroni et al., 2013; Martens et al., 2014) . Preclinical studies and clinical tests have demonstrated a number of promising applications of MSC in regenerative medicine (Aurrekoetxea et al., 2015; Bianco, 2014; Caplan, 2007; Christ et al., 2015; Kim et al., 2012; Levi and Longaker, 2011; Momin et al., 2010; Phinney and Prockop, 2007; Psaltis et al., 2008; Rastegar et al., 2010; Reiser et al., 2005; Wakitani et al., 2011) .
Stem cells including MSC reside in a highly specialized microenvironment termed the stem cell niche (Scadden, 2006) . The stem cell niche is hypoxic, a condition that is important in maintaining stem cells in an undifferentiated state .
It is known that hypoxia stimulates ATP release (Dutta et al., 2004; Kahlin et al., 2014; Lim To et al., 2015; Mortensen et al., 2011; Orriss et al., 2009; Roger et al., 2015 ). An increasing number of studies show that under in vitro culture conditions and in vivo, MSC release ATP and other nucleotides constitutively or in response to mechanical or chemical stimulation, via vesicular exocytosis, connexin hemi-channel or other yet defined mechanisms (Biver et al., 2013; Coppi et al., 2007; Kawano et al., 2006; Kwon, 2012; Riddle et al., 2008; Riddle et al., 2007; Sun et al., 2013; Weihs et al., 2014) . Extracellular nucleotides can impose significant regulation of MSC functions. It is worth pointing out that MSC also express ecto-nucleotidases on the cell surface that metabolize extracellular ATP and other nucleotides (Noronha-Matos and Correia-de-Sa, 2016; Roszek et al., 2015; Scarfi, 2014) . Indeed, adenosine as an ATP metabolite has been proposed to contribute in ATP regulation of MSC functions via activating the adenosine P1 receptors (Carroll et al., 2012; Ciciarello et al., 2013; Gharibi et al., 2011; Shih et al., 2014) . Several recent reviews have appeared that focus on various aspects of the purinergic signalling mediated by the adenosine P1, P2X and P2Y receptors and ecto-nucleotidases in MSC, particularly in osteogenic differentiation (Cavaliere et al., 2015; Lenertz et al., 2015; Noronha-Matos and Correia-de-Sa, 2016; Scarfi, 2014) . In this review, we discuss the current understanding of the P2 receptor-mediated purinergic signalling in MSC, with respect to expression of the P2X and P2Y receptors and their roles in mediating extracellular nucleotide regulation of MSC proliferation, viability, migration and differentiation into adipocyte, osteoblast, chondrocytes, neuronal and glial cells. We aim this review to provide a more inclusive overview of the findings reported by recent studies, prompting the reader to bear in mind the noticeable discrepancies currently existing in the literature.
Expression of P2 receptors in MSC
Expression of the P2X and P2Y receptors in MSC has been examined at the mRNA level, using conventional or real time reverse transcription-polymerase chain reaction (RT-PCR), and at the protein level, using western blotting or immunocytochemistry. Their functional expression has been studied by measuring agonist-induced responses, often using fluorescent imaging to monitor agonist-evoked change in the [Ca 2+ ]i, in conjunction with using selective antagonists to inhibit the receptor activity or small interference RNA (siRNA) to reduce the receptor expression. Table 1 summarizes the P2X and P2Y
receptors that have been reported in MSC of various species and tissues, and the methods used to shown their expression, which gives a quick reference to the reader. However, studies using MSC from different species, particularly different tissues, have reported a considerably variable expression profile for both P2X and P2Y receptors, noticeably at the protein and functional expression levels. For simplicity, we discuss expression of the P2X and P2Y receptors according to the tissue origins of MSC used.
P2X receptors
BM-MSC. Expression of the P2X receptors in bone marrow derived MSC (BM-MSC) was firstly examined in two independent studies (Coppi et al., 2007; Riddle et al., 2007) .
Coppi et al showed, using patch-clamp recording, that ATP evoked an inwardly-rectifying current with a reversal potental close to 0 mV in a subset of human BM-MSC (Coppi et al., 2007) . In addition, exposure of such cells to ATP caused membrane deploarization.
Treatment with pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS), a generic P2 antagonist, reduced ATP-induced inward currents and led to membrane hyperpolarization. These results were interpreted to indicate functional expression of the P2X receptor(s) (Coppi et al., 2007) , but the molecular identity of the receptor(s) mediating ATP-induced inward currents was not established. The second study showed P2X7 protein expression in human BM-MSC, using western blotting (Riddle et al., 2007) .
Ferrati et al were the first to systematically assess expression of the P2X receptors in human BM-MSC, and reported mRNA expression for all the P2X subunits, with the exception of P2X2, and protein expression for P2X1, P2X4 and P2X7 (Ferrari et al., 2011) .
The P2X7 protein expression in human BM-MSC has been further demonstrated in two recent studies, using western blotting (Sun et al., 2013) and immunocytochemistry (Noronha-Matos et al., 2014) . Ferrati et al also studied, using Ca 2+ imaging, the role of the P2X receptors in ATP-induced Ca 2+ signalling in human BM-MSC (Ferrari et al., 2011 ]i was almost completely abolished by KN62, a human P2X7 selective antagonist, and oxidized ATP (oxATP), an irreversible P2X7 inhibitor (Ferrari et al., 2011) , indicating ATP-induced Ca 2+ influx is mainly mediated by the P2X7 receptor.
In a more recent study, in addition to a sustained increase in the [Ca 2+ ]i, ATP also evoked membrane blebbing and large pore formation (Noronha-Matos et al., 2014) , which are characteristics of the P2X7 receptor activation (Virginio et al., 1999; Wei et al., 2016) .
Moreover, 2',3'-(benzoyl-4-benzoyl)-ATP (BzATP), another ATP synthetic analogue with a greater potency than ATP at the P2X7 receptor, was more potent than ATP in raising the [Ca 2+ ]i, membrane blebbing and large pore formation. BzATP-induced effects were blocked by A-438079, a P2X7 selective antagonist (Noronha-Matos et al., 2014) , providing further evidence to support functional expression of the P2X7 receptor in human BM-MSC. A recent study has shown P2X7 mRNA and protein expression in rat BM-MSC (Li et al., 2015) . As discussed further below, this study has found that BzATPinduced regulation of adipogenic and osteogenic differentiation was attenuated by brilliant blue G (BBG), a P2X7 selective antagonist, and P2X7-specific siRNA, demonstrating functional expression of the P2X7 receptor and an important role in the regulation of differentiation (Li et al., 2015) . Kwon reported oscillations in the extracellular ATP level in mouse BM-MSC, which are dependent of the intracellular Ca 2+ level (Kwon, 2012) . Such ATP oscillations were prevented by 5-BDBD, a P2X4 selective antagonist. These observations have led to the notion that the functional P2X4 receptor mediates ATP-induced Ca 2+ influx as part of an autocrine signaling mechanism resulting in the ATP oscillations (Kwon, 2012) .
AT-MSC. Expression of the P2X receptors in human adipose tissue derived MSC (AT-MSC) was firstly exmained by Zippel and colleagues (Zippel et al., 2012) . The study reported mRNA expression for P2X3-P2X7, but not P2X1 and P2X2, and protein expression for P2X5-P2X7, using western blotting. They showed that ATP elicited an increase in the [Ca 2+ ]i, which was prevented by suramin, another P2 generic antagonist, and attenuated by NF279 at a concentration (100 µM), which is known to inhibit multiple P2X receptors including P2X1 (Rettinger et al., 2000) . A recent study has evaluated expression of the P2X receptors in rat AT-MSC and observed mRNA expression for P2X3
and P2X4, but not any other P2X subunits (Faroni et al., 2013) . The protein expression for P2X4 and P2X7 was examined, using western blotting, but not detectable. ATP increased the [Ca 2+ ]i in a concentration-dependent manner (10-1000 µM) with the concentration evoking half of the maximum (EC50) of approximately 30 µM. In agreement with the lack of P2X7 mRNA expression, ATP-induced Ca 2+ response was insensitive to inhibition by AZ10606120, a P2X7 selective antagonist (Faroni et al., 2013) .
UC-MSC. In human umbilical cord derived MSC (UC-MSC), the mRNA transcript was detected for P2X1 and P2X4-P2X7, but not P2X2 and P2X3 (Tu et al., 2014) . As discussed further below, this study has shown that ATP stimulated neuronal differentiation, which was prevented by 2',3'-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) (Tu et al., 2014) at a concentration (30 µM), which is known to inhibit several P2X receptors including the P2X1 and P2X4 receptors (Virginio et al., 1998) . These results suggest functional expression of the P2X receptor(s) in human UC-MSC, but the molecular identity of the P2X receptor(s) was not established.
PDL-MSC. It remains unclear whether the P2X receptors are expressed in human periodontal ligament derived MSC (PDL-MSC), with an exception of the P2X7 receptor.
The P2X7 expression has been documented at the mRNA and protein levels in human PDL-MSC (Trubiani et al., 2014) . In addition, BzATP induced a monophasic increase in the [Ca 2+ ]i and large pore formation, which were inhibited by oxATP. BzATP also induced release of interleukin-8 (IL-8) and CC chemokine ligand 20 (CCL20), which was suppressed by A-740003, a P2X7 selective antagonist, as well as oxATP (Trubiani et al., 2014) . There results support functional expression of the P2X7 receptor in human PDL-MSC and an important role in mediating the immunomodulatory property of MSC.
DP-MSC. Expression of the P2X receptors in human dental pulp derived MSC (DP-MSC) has been reently investigated by us (Peng et al., 2016 ]i was insensitive to inhibition by the P2X4 antagonist 5-BDBD. In contrast, the increases in the [Ca 2+ ]i induced by both ATP and BzATP were attenuated by AZ11645373, a human P2X7 selective antagonist, and P2X7-specific siRNA, leading to the conclusion that functional expression of the P2X7 receptor contributes in mediating ATP-induced Ca 2+ signaling in human DP-MSC (Peng et al., 2016) .
P2Y receptors

BM-MSC. Ferrari et al performed RT-PCR analysis of the P2Y receptors in human BM-
MSC and showed mRNA expression for all eight P2Y receptors (Ferrari et al., 2011) .
Several groups examined protein expressio of the P2Y receptors in human BM-MSC and the results are not completely consistent. An early study, using western blotting, showed protein expression for P2Y2, P2Y6 and P2Y11, but not P2Y1, P2Y4 and P2Y12 (Riddle et al., 2007) . Ferrari et al, also using western blotting, confirmed the protein expression for P2Y2 and P2Y11, and, additionally. they reported P2Y1 protein expresssion (Ferrari et al., 2011 oscillations in a subset of human BM-MSC (Kawano et al., 2002) . In the follow-up study, they showed that Ca 2+ oscillations promoted nuclear translocation of nuclear factor of activated T cells (NFAT) (Kawano et al., 2006) . Moreover, such spontaneous Ca ]i (Ferrari et al., 2011; Noronha-Matos et al., 2014) .
Thirdly, in addition to the above-discussed inward currents, ATP also induced outward K + currents in a subset of human BM-MSC that exhibited strong dependence of the intracellular Ca 2+ level as well as membrane potential (Coppi et al., 2007) . Such Ca 2+ -dependent K + outward currents were prevented by PPADS and MRS2179, a P2Y1 selective antagonist, indicating that Ca 2+ release after activaiton of the P2Y1-G ,q-PLC-IP3R signalling pathway triggers ATP-induced K + outward currents. Finally, as discussed further below, ATP-stimulated adipogenic differentiation of human BM-MSC was inhibited by MRS2279, another P2Y1 specific antagonist (Ciciarello et al., 2013) .
In addition to the P2Y1 receptor, ATP also activates the P2Y2 and P2Y11 receptors. abolished by NF157, a selective P2Y11 antagonist, and P2Y11-specific siRNA, but they were not affected with oxATP or KN62 (Fruscione et al., 2010 responses favors functional expression of the P2Y2 receptor (Ichikawa and Gemba, 2009 ).
Consistently, as discussed further below, a recent study has shown that UTP-induced regulation of osteogenic and adipogenic differentiation of rat BM-MSC was prevented by P2Y2-specific siRNA, but not P2Y4-specific siRNA or MRS2578, the P2Y6 selective antagonist . There were remarkable differences in adipogenic and osteogenic differentiation of BM-MSC from the wild-type (WT) and P2Y13 knockout (KO) mice, indicating functional expression of the P2Y13 receptor in mouse BM-MSC (Biver et al., 2013) .
AT-MSC. Expression of the P2Y receptors in human AT-MSC was studied (Zippel et al., 2012) . All the P2Y receptors were detected at the mRNA level, and the P2Y1, P2Y2, P2Y4
and P2Y11 were further demonstrated at the protein level, using western blotting. UTP and 2-methylthio-ADP, an agonist at the P2Y1 and P2Y11-P2Y13 receptors, elevated the [Ca 2+ ]i, whereas NF546, a P2Y11 selective agonist, did not. ATP-induced increase in the [Ca 2+ ]i was reduced by the P2X receptor antagonist NF279 inhibitor as discussed above, and was also attenuated by pertussis toxin (PTX), the G ,i inhibitor, supporting involvement of the G ,i-coupled P2Y receptors. Moreover, ATP and UDP-glucose suppressed adipogenic differentiation (Zippel et al., 2012) . These results provide evidence to support functional expression of the P2Y receptors including P2Y14, but not P2Y11.
However, the P2Y receptors that mediate ATP-and UTP-induced Ca 2+ signaling in human AT-MSC remain not fully understood.
DP-MSC. The role of the P2Y1, P2Y2 and P2Y11 receptors in mediating ATP-induced Ca 2+ signalling in human DP-MSC has been investigated in our recent study (Peng et al., 2016) . While mRNA expression for P2Y1 and P2Y11 was consistently observed in human DP-MSC from different donors, P2Y2 mRNA transcript was undetectable or at a very low level (Peng et al., 2016 
Proliferation and viability
Several studies have evaluated the effects of ATP and NAD, released endogenously or applied exogenously, on BM-MSC proliferation and viability (Coppi et al., 2007; Ferrari et al., 2011; Fruscione et al., 2011; Li et al., 2015; Li et al., 2016; Riddle et al., 2007) . However, it was not established whether or which of these receptors mediated the increase in cell proliferation in response to fluid flow or ATP. A separate study, using luminescence assay, found that the ATP content was significantly higher in the culture medium in the presence of human BM-MSC, suggesting spontaneous release of ATP (Coppi et al., 2007) .
In addition, the number of cells after 5 days in culture was increased by inclusion of PPADS or the P2Y1 antagonist MRS2179 in the culture medium, and decreased by addition of ATP (10 µM). These results suggest that ATP inhibits cell proliferation at least in part via activation of the P2Y1 receptor. Ferrari et al profiled the gene expression in human BM-MSC with or without treatment with 1 mM ATP for 24 hours (Ferrari et al., 2011) . ATP up-regulated the expression of growth arrest genes and cell cycle inhibitors, and down-regulated the expression of genes related to cell cycle, DNA replication and repair, cell division and chromosome segregation. Consistently, they showed that pretreatment of human BM-MSC with 1 mM ATP for 24-72 hours inhibited cell proliferation, assessed after cells were cultured for 5 days, but pretreatment with ATP at lower concentrations (1-100 µM) was without effect (Ferrari et al., 2011) . Fruscione et al showed, using thiazol blue tetrazolium bromide (MTT) cell viability assay, that the number of human BM-MSC was increased after they were cultured in the presence of NAD for 72 hours (Fruscione et al., 2011) . ]i was much greater in cells at high density. In addition, UTP induced Ca 2+ oscillations in cells but only at medium density, which depended on the store-operated Ca 2+ entry. As the cell density increased, the P2Y2 mRNA level was increased. Furthermore, the percentage of proliferating cell nuclear antigen-positive cells, as identified using immunocytochemistry, was 93% at low density, which was reduced by about half at medium density and further down to nearly zero at high density. These results were interpreted to suggest cell density-dependent changes in the P2Y2 expression and intracellular Ca 2+ mobilization that may relate to cell cycle progression. Two recent studies from the same group have reported that BzATP and UTP, both applied at 5-125 µM, did not alter the number of rat BM-MSC after they were cultured for 7 days, evaluated using cell counting kit-8 (CCK-8) assay (Li et al., 2015; Li et al., 2016) .
Cell proliferation and viability of MSC from other tissues have also been examined.
Human DP-MSC proliferated in the presence of ATP at 0.3-300 µM for 72 hours in a similar rate as they did in the absence of ATP, as shown in our recent study based on both cell counting and MTT assay (Peng et al., 2016) . A recent study, using MTT assay, has documented that the human PDL-MSC viability was considerably reduced after cultured in the presence of BzATP at 30-300 µM for 48 hours (Trubiani et al., 2014) . As discussed below, this study has shown functional expression of the P2X7 receptor, but it was not clear whether the P2X7 receptor is critical in BzATP-induced reduction in the cell viability.
In summary, studies have shown extracellular nucleotide regulation of MSC proliferation and viability and a significant role for the P2Y1 and P2Y11 receptor in the regulation of BM-MSC proliferation by ATP and NAD respectively. However, the effects of extracellular nucleotides on MSC proliferation and viability are highly variable, and even ATP-induced effects are noticeably different. These discrepancies may associate with MSC used, due to factors like the donor age and tissue origin, which as discussed above express the P2X and P2Y receptors at different levels, and may also relate to the experimental conditions, such as concentration, treatment duration and assays used.
Cell migration
Studies have drawn attention to whether extracellular nucleotides regulate MSC migration and their homing ability in vivo (Ferrari et al., 2011; Fruscione et al., 2011; Peng et al., 2016) . Ferrari et al showed, using trans-well migration assay, that addition of ATP to the upper chamber enhanced human BM-MSC migration (Ferrari et al., 2011) .
When added to the lower chamber as a chemotactic stimulus, ATP had no effect but increased the chemotactic activity of chemokine CXCL-12. In contrast, UTP induced no effect. In addition, pretreatment with 1 mM ATP enhanced the homing rate of human BM-MSC, assessed 16 hours after injected into immunocompromised mice (Ferrari et al., 2011) . However, the P2 receptor(s) that mediate(s) ATP-induced stimulation of cell migration was (were) not identified. Fruscione et al examined NAD regulation of human BM-MSC migration, also using trans-well assay (Fruscione et al., 2011) .
Pretreatment with NAD stimulated cell migration, whereas pretreatment with NADase was without effect. NAD also enhanced cell migration when added to the lower chamber.
NAD-induced increase in cell migration was prevented by the P2Y11 antagonist NF157
and ddA, an inhibitor of membrane-associated AC, supporting a key role of the P2Y11-G ,i-AC-cAMP signalling pathway (Fruscione et al., 2011) . The same study also showed that pretreatment with ATP (1-10 µM) or addition of ATP in the lower chamber stimulated cell migration. Again, the molecular identity of the P2 receptor(s) involved in ATPinduced stimulation of cell migration was not clearly defined (Fruscione et al., 2011) .
Our recent study has shown that human DP-MSC migration was accelerated in the presence of ATP at 30 µM but not 3 µM, assessed at 24, 48 and 72 hours mainly using wound healing assay (Peng et al., 2016) . ATP-induced stimulation of cell migration was inhibited by PPADS, the human P2X7 antagonist AZ1164373, or specific siRNA targeting the P2X7, P2Y1 or P2Y11 receptor, but not CGS15943, a generic antagonist for adenosine receptors. These results suggest engagement of these three P2 receptors but not the adenosine receptors. Our study has also shown that activation of the Orai1 CRAC channel as an important downstream mechanism mediates ATP-induced stimulation of cell migration (Peng et al., 2016) .
In summary, studies have gathered consistent evidence to demonstrate that both ATP and NAD stimulate human MSC migration. While activation of the P2Y11-G ,i-AC-cAMP signalling pathway is critical for NAD-induced stimulation of human BM-MSC, several P2 receptors, including the P2X7, P2Y1 and P2Y11 receptors, participate in ATP-induced stimulation of human DP-MSC.
Adipogenic differentiation
MSC are well-documented to commit differentiation to adipocyte. There is evidence to show substantial changes in the expression of both P2X and P2Y receptors during adipogenic differentiation. Two recent studies from the same group have shown that after rat BM-MSC were cultured in adipogenic medium for 7 day, the P2X7 mRNA and protein expression was down-regulated (Li et al., 2015) and by contrast the P2Y2 mRNA expression was up-regulated . Zippel et al reported that the mRNA expression was increased for P2X6 and P2Y11 and decreased for P2Y4 and P2Y14 after adipogenic differentiation of human AT-MSC (Zippel et al., 2012) . The change in expression for P2X6, P2Y4 and P2Y11 was also demonstrated at the protein level, using western blotting. Furthermore, after adipogenic differentiation, the increases in the [Ca (Li et al., 2015) .
Studies using agonists and antagonists provide evidence to show that various P2Y
receptors play a significant role in extracellular nucleotide regulation of adipogenic gene expression and lipid droplet formation during adipogenic differentiation of MSC.
Ciciarello et al showed that treatment of human BM-MSC with 1 mM ATP for 24 hours, prior to adipogenic differentiation, enhanced the PPAR expression and also fat droplet formation, examined two and three weeks after adipogenic differentiation (Ciciarello et al., 2013) . ATP-induced increase in the PPAR expression was inhibited by the P2Y1 antagonist MRS2279, but not by the P2Y6 antagonist MRS2578, P2Y11 antagonist NF340, P2Y12 antagonist ARC66096 or P2X7 antagonist KN62. Pretreatment with UTP or INS45973, an agonist at the P2Y2 and P2Y4 receptors, resulted in a similar effect on the PPAR expression, whereas the P2Y2 selective agonist MRS2768 was ineffective. These results have been interpreted to support a critical role for the P2Y1 and P2Y4 receptors in regulation of adipogenic differentiation of human BM-MSC by ATP and UTP, respectively (Ciciarello et al., 2013) . However, ATP-induced increase in the PPAR expression was also inhibited by the G ,i inhibitor PTX (Ciciarello et al., 2013) , suggesting involvement of the G ,i-coupled P2Y receptors. In support of no significant role for the P2Y11 receptor in adipogenic differentiation, an earlier study showed that during adipogenic differentiation of human BM-MSC, activation or inhibition of NADinduced P2Y11-mediated signaling resulted in no effect on the expression of PPAR, FABP4 and adiponectin, and lipid droplet formation (Fruscione et al., 2010) . A recent study using BM-MSC derived from the WT and P2Y13-KO mice has shown that P2Y13 deficiency led to earlier expression of PPAR isoform 2 (PPAR2), an early adipogenic gene, elevated expression of adipsin, and lipid droplet formation (Biver et al., 2013) .
Furthermore, there was an increase in the number of bone marrow adipocytes in the P2Y13-KO mice. These results have disclosed an important role for the P2Y13 receptor in suppressing adipogenic differentiation of mouse BM-MSC (Biver et al., 2013) . A more recent study has investigated the effect of UTP (5-125 µM) on adipogenic differentiation of rat BM-MSC . Inclusion of UTP in adipogenic medium enhanced the mRNA expression of PPAR, FABP4 and adipsin, and fat droplet formation. UTPinduced increase in the expression of adipogenic genes was inhibited by P2Y2-specific siRNA, but not P2Y4-specific siRNA or the P2Y6 antagonist MRS2578, suggesting strong dependence of the P2Y2 receptor . Like BzATP as discussed above, initial treatment with UTP (5-10 min) activated, but prolonged treatment (20-60 min)
inhibited, the ERK signaling. However, treatment with UTP resulted in no effect on the JNK and p38 MAPK signaling. UTP-induced ERK activation was prevented by P2Y2-specific siRNA. The ERK activity in both control and UTP-treated cells was completely abolished upon treatment with the ERK signaling inhibitor UO126. When UO126 was added to adipogenic medium, UTP-induced increase in the expression of adipogenic genes was completely inhibited on the first day, but was persistently observed after treatment with UO126 for 3 and 7 days . These results indicate that the ERK signalling pathway is involved in the early stage of UTP up-regulation of adipogenic differentiation.
Inclusion of PPADS during adipogenic differentiation of human AT-MSC attenuated lipid droplet formation, and such an inhibition was mitigated by co-application of exogenous UTP but not ATP, suggesting involvement of the P2Y4 but not P2Y2 receptor (Zippel et al., 2012) , which is different from the finding from the above-discussed study of human BM-MSC by Ciciarello et al (Ciciarello et al., 2013) . Application of UTP, BzATP or ADP alone was without effect on lipid droplet formation. However, application of ATP alone reduced and, in contrast, treatment with apyrase enhanced, lipid droplet formation, suggesting that endogenously released ATP or its metabolites inhibit adipogenic differentiation. Like ATP, UDP-glucose reduced lipid droplet formation.
These observations, together with down-regulated P2Y14 expression during adipogenic differentiation discussed above, supports the notion that activation of the P2Y14 receptor inhibits adipogenic differentiation of human AT-MSC (Zippel et al., 2012) .
To summarize, studies provide evidence to show extracellular nucleotide regulation of adipogenic differentiation of MSC via activation of different P2 receptors. Activation of the P2X7, P2Y13 or P2Y14 receptor down-regulates, whereas activation of the P2Y1, P2Y2 or P2Y4 receptor up-regulates, adipogenic differentiation.
Osteogenic differentiation
The bone-forming cell, osteoblast, is also differentiated from MSC. As during adipogenic differentiation discussed above, studies have documented changes in the expression of the P2X and P2Y receptors during osteogenic differentiation of MSC. Again, there are substantial variations in the reported results. During osteogenic differentiation of human BM-MSC, the protein expression was decreased for P2X7 and P2Y1, increased for P2Y2
and P2Y4, and remained unaltered for P2Y6 (Noronha Matos et al., 2012) . However, during osteogenic differentiation of rat BM-MSC, the P2X7 mRNA expression was elevated (Li et al., 2015) but the P2Y2 mRNA expression was reduced .
The P2Y13 mRNA expression was up-regulated during osteogenic differentiation of mouse BM-MSC (Biver et al., 2013) . After osteogenic differentiation of human AT-MSC, the mRNA and protein expression was down-regulated for P2X6, P2X7, P2Y1, P2Y2 and P2Y4 and up-regulated for P2X5, and the P2Y14 mRNA expression was also decreased (Zippel et al., 2012) .
It is well-documented that during osteogenic differentiation, a number of genes including alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx2), osterix, osteocalcin and osteopontin, are expressed or their expression is up-regulated.
Osteoblast is responsible for bone extracellular matrix production and mineralization.
These genotypes and phenotypes have been commonly used to indicate osteogenic differentiation of MSC. Treatment of human BM-MSC with ATP or shockwave, a mechanical stimulus inducing endogenous ATP release, increased the ALP activity, osteocalcin protein expression, and matrix mineralization (Sun et al., 2013) . These effects were strongly reduced or completely abolished by PPADS, the human P2X7 antagonist KN62 and P2X7-specific siRNA. Shockwave-induced effects were also prevented by apyrase, supporting a role for endogenous ATP release. In addition, both ATP and shockwave induced robust increases in the expression of c-Fos and c-Jun. Furthermore, all these effects were inhibited by SB203850, an inhibitor of the p38 MAPK signalling (Sun et al., 2013) . These findings have led to the conclusion that activation of the P2X7 receptor triggers the p38 MARK signalling pathway to induce the expression of c-Fos and c-Jun, which together form the transcription factor activating protein-1 to up-regulate the expression of osteogenic genes (Sun et al., 2013) . (Li et al., 2015) . These effects were inhibited by the P2X7 antagonist BBG. As discussed above, BzATP induced activation of the ERK and JNK but not p38 MAPK signalling pathways in rat BM-MSC, and BzATP-induced increase in the expression of the osteogenic genes was prevented by the ERK signalling inhibitor U0126 and the JNK signalling inhibitor SP600125. Taken together, these studies support the idea that activation of the P2X7 receptor triggers the Rho and/or MAPK downstream signalling pathways to up-regulate osteogenic differentiation of BM-MSC (Li et al., 2015) .
There is evidence to support a role for the P2Y receptors in extracellular nucleotide regulation of osteogenic differentiation. UTP, UTPS, the non-hydrolysable UTP analogue, UDP, and PSB0474, a metabolically stable P2Y6 agonist, were potent in inducing an increase in the ALP activity in human BM-MSC (Noronha Matos et al., 2012) . Enhancement in osteogenic differentiation induced by these agonists was inhibited by PPADS and the P2Y6 antagonist MRS2578 (Noronha Matos et al., 2012) .
These results support a critical role for the P2Y6 receptor. However, treatment with UTP of rat BM-MSC down-regulated the expression of Runx2, ALP and osteopontin . Such down-regulation in the expression of osteogenic genes was attenuated by P2Y2-specific siRNA, but not P2Y4-siRNA or the P2Y6 antagonist MRS2578, indicating main involvement of the P2Y2 receptor . Furthermore, UTP-induced inhibition of osteogenic differentiation was prevented during the first 24 hour treatment with the ERK signalling inhibitor UO126, but was unabated after treatment with UO126 was extended to 3 and 7 days . This result suggests that the ERK signalling pathway is mainly involved in the early stage of UTP down-regulation of adipogenic differentiation. Activation of the P2Y13 receptor in mouse BM-MSC by ADP up-regulated the expression of ALP and osterix and, BM-MSC from the P2Y13-KO mouse exhibited preferential adipogenic differentiation, consistently highlighting that activation of the P2Y13 receptor is necessary for commitment of BM-MSC to osteogenic differentiation (Biver et al., 2013 ).
An early study by Zippel et al showed that treatment of human AT-MSC with suramin, PPADS or apyrase during osteogenic differentiation inhibited matrix mineralization (Zippel et al., 2012) . Such an inhibition was reversed by co-application of ATP but not UTP, excluding a major role for the P2Y2 or P2Y4 receptor. However, it was not clearly established which P2 receptor(s) mediate(s) the inhibition of osteogenic differentiation by suramin and PPADS (Zippel et al., 2012) .
In summary, it is evident that extracellular nucleotide regulation of osteogenic differentiation of MSC via activation of the P2X and/or P2Y receptors. More specifically, activation of the P2X7, P2Y6 or P2Y13 receptor up-regulates, and activation of the P2Y2 receptor down-regulates, osteogenic differentiation. Of notice, activation of the P2X7, P2Y2 and P2Y13 receptors results in an opposite regulation of adipogenic and osteogenic differentiation, which is not surprising considering that MSC differentiation into adipocyte and osteoblast often shows mutual exclusion (Chen et al., 2016) .
Chondrogenic differentiation
Chondrocyte represents the third lineage of MSC differentiation. Our current knowledge with regards to extracellular regulation of chondrogenic differentiation of MSC is limited.
The expression of chondrogenic genes such as aggrecan, type II collagen and SOX9 is up-regulated during chondrogenic differentiation. A previous study using ATD5, a prechondrogenic cell that can differentiate into chondrocytes, showed an important role for ATP oscillations in pre-chondrogenic condensation, which were driven by intracellular Ca 2+ oscillations (Kwon, 2012) . Similar ATP oscillations and increase in the expression of the above-described chondrogenic genes were observed in the micromass culture of mouse BM-MSC during chondrogenic differentiations, which were lost by treatment with the P2X4 antagonist 5-BDBD (Kwon, 2012) . These results support ATP-induced P2X4
receptor-mediated Ca 2+ influx is required in the ATP oscillations and chondrogenic differentiation of mouse MSC (Kwon, 2012) .
Neuronal differentiation
Astrocyte, one type of glial cells in the central nervous system, is well-known to release ATP, which is critical for Ca 2+ wave propagation among astrocytes and modulation of synaptic transmission (Haydon and Carmignoto, 2006) . A recent study has examined the effects of ATP released from astrocytes or exogenously applied on neuronal differentiation of human BM-MSC (Tu et al., 2014) . 
Glial differentiation
There is evidence to suggest that rat AT-MSC can differentiate into cells with Schwann cell (SC) phenotypes, such as expression of glial markers and growth factors, and an ability to produce myelin and induce neurite outgrowth in vitro and enhance nerve regeneration in vivo, and a recent study has examined the expression of P2X receptors after rat AT-MSC were differentiated into SC-like cells (Faroni et al., 2013) . As discussed above, in rat AT-MSC, P2X4 and P2X7 at the protein level were not detected but became readily detected after differentiation into SC-like cells. Consistently, ATP-induced increase in the [Ca 2+ ]i in SC-like cells were sensitive to inhibition by the P2X7 antagonist AZ10606120, which was not observed in AT-MSC. ATP was also more potent, with EC50
reduced from ~100 µM in AT-MSC to below 30 µM in SC-like cells. Furthermore, in patch-clamp recording, both ATP and BzATP concentration-dependently induced nonsensitizing currents in SC-cells and BzATP was potent more than ATP (Faroni et al., 2013) .
ATP-induced currents were abolished by the P2X7 antagonist AZ10606120. All these results provide consistent evidence to indicate functional expression of the P2X7 receptor in SC-like cells. It is long known that the P2X7 receptor as a cytolytic receptor because sustained activation of the P2X7 receptor causes cell death (Jiang, 2009; Virginio et al., 1999) . Exposure of SC-like cells to 5 mM ATP for 1 hour induced cell death as determined by lactate dehydrogenase release cytotoxicity assay and EthD-1 staining viability assay (Faroni et al., 2013) . ATP-induced SC-like cell death was prevented by AZ10606120.
These results further support up-regulation of the P2X7 receptor expression during
Schwann cell differentiation of AT-MSC (Faroni et al., 2013) . However, it remains unclear whether extracellular nucleotides regulate glial differentiation of MSC and whether up-regulation of the P2X7 receptor expression is causatively involved in the regulation of glial differentiation.
Concluding remarks and perspectives
It is evident from the discussion above that studies in the past few years have significantly enriched our knowledge with respect to expression of the P2X and P2Y receptors in MSC, and also provided evidence to support a role for these receptors in mediating the regulation of MSC viability, proliferation, migration and differentiation by extracellular nucleotides, particularly ATP and UTP. However, it is also obvious that substantial discrepancies exist in the findings from studies examining MSC from different species and tissues, even MSC from the same type species and tissue. More investigations are clearly required to gain a better understanding of extracellular nucleotide regulation of MSC functions and the role of the P2X and P2Y receptors in such functional regulation.
Currently, it is completely unclear whether extracellular nucleotides are important in maintaining MSC stemness, namely, MSC in the self-renewal and undifferentiated state, and if they are, it is important to determine the role of the P2X and P2Y receptors. Ca 2+ is a ubiquitous intracellular messenger that plays a crucial role in a vast range of cell functions (Berridge et al., 2003 (Agell et al., 2002; Argentaro et al., 2003; Preß et al., 2015; Stoeckl et al., 2013; Zayzafoon, 2006) . Indeed, as discussed above, emerging evidence supports that activation of the P2X7 and P2Y receptors triggers the Rho and/or MAPK signaling pathways in the regulation of adipogenic and osteogenic differentiation of MSC.
More remain to be learnt in terms of the Ca 
